Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Deanna L. Haasch"'
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Table S1: ABT-165 binding affinity; Table S2: ABT-165 in vitro potency; Table S3: Effect of VEGF on anti-DLL4 cellular potency of ABT-165; Table S4: Summary of in vivo efficacy; Table S5: Key safety findings of ABT-487 and ABT-165; Figure S1: Serum c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948fdfba3f05b8a422e19034176fe36d
https://doi.org/10.1158/1535-7163.22505686
https://doi.org/10.1158/1535-7163.22505686
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
This file describes the binding assay details of surface plasmon resonance technology, ligand and receptor binding competition assays, western blot detection of DLL4 protein down-regulation, and the methods to measure total circulating soluble DLL4 a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::267ca9367d459176dea46bdd55158c64
https://doi.org/10.1158/1535-7163.22505689.v1
https://doi.org/10.1158/1535-7163.22505689.v1
Autor:
Susan E. Morgan-Lappe, Jijie Gu, Louie Naumovski, Sherry L. Ralston, Wenqing Gao, Surekha S. Akella, Catherine Zhang, Sarah R. Mudd, Fang Jiang, Sanjay C. Panchal, Enrico L. DiGiammarino, Lucia J. Eaton, Kelly D. Foster-Duke, Deanna L. Haasch, Dominic J. Ambrosi, Jonathan A. Hickson, Yingchun Li
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2454e519448df5024c51607be68974ce
https://doi.org/10.1158/1535-7163.c.6538150.v1
https://doi.org/10.1158/1535-7163.c.6538150.v1
Autor:
Susan E. Morgan-Lappe, Wenqing Gao, Enrico L. Digiammarino, Yingchun Li, Surekha S. Akella, Sanjay C. Panchal, Jonathan Hickson, Sarah R. Mudd, Louie Naumovski, Jijie Gu, Ralston Sherry L, Dominic J. Ambrosi, Catherine Zhang, Kelly Foster-Duke, Lucia Eaton, Fang Jiang, Deanna L. Haasch
Publikováno v:
Molecular Cancer Therapeutics. 17:1039-1050
Antiangiogenic therapy is a clinically validated modality in cancer treatment. To date, all approved antiangiogenic drugs primarily inhibit the VEGF pathway. Delta-like ligand 4 (DLL4) has been identified as a potential drug target in VEGF-independen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c6f9d4850f963b7e646c9f59b8c47c7
https://doi.org/10.1158/1535-7163.mct-17-0800
https://doi.org/10.1158/1535-7163.mct-17-0800
Autor:
Cele Abad-Zapatero, Yong Jia, David J. Burns, Timothy E. Cloutier, Zhili Xin, Douglas Marcotte, Hua Tang, Kenneth M. Comess, Teresa I. Ng, David W. Borhani, Michael L. Coen, Sanyi Wang, Harriet T. Smith, Eric R. Goedken, Danying Song, Jill E. Clampit, Bo Liu, Philip J. Hajduk, Xueheng Cheng, Maria A. Argiriadi, David Banach, Chaohong Sun, Duncan R. Groebe, Elizabeth H. Fry, Christopher Quinn, Gang Liu, David J. Calderwood, Deanna L. Haasch, Vincent S. Stoll, Rebecca J. Gum
Publikováno v:
ACS Chemical Biology. 6:234-244
Inhibition of protein kinases has validated therapeutic utility for cancer, with at least seven kinase inhibitor drugs on the market. Protein kinase inhibition also has significant potential for a variety of other diseases, including diabetes, pain,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b24a8e4dd5ebafebd0f1d8db41a15f68
https://doi.org/10.1021/cb1002619
https://doi.org/10.1021/cb1002619
Autor:
Deanna L. Haasch, Hing L. Sham, Rebecca J. Gum, James M. Trevillyan, Elizabeth H. Fry, Cele Abad-Zapatero, Gang Liu, Mei Liu, Jill E. Clampit, Sanyi Wang, Cristina M. Rondinone
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 17:668-672
A new series of 4-anilinopyrimidines has been synthesized and evaluated as JNK1 inhibitors. SAR studies led to the discovery of potent JNK1 inhibitors with good enzymatic activity as well as cellular potency represented by compound 2b. Kinase selecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113d54228f101f627d32e8d9184ef361
https://doi.org/10.1016/j.bmcl.2006.10.093
https://doi.org/10.1016/j.bmcl.2006.10.093
Autor:
Hing L. Sham, Zhili Xin, Christi Kosogof, Terry Pederson, Hongyu Zhao, Cele Abad-Zapatero, Bo Liu, Michael D. Serby, Bruce G. Szczepankiewicz, Gang Liu, Cristina M. Rondinone, Nelson Lissa T, Deanna L. Haasch, Jill E. Clampit, Sanyi Wang, Rebecca J. Gum, James M. Trevillyan, Elizabeth H. Fry, Eric F. Johnson, Mei Liu
Publikováno v:
Journal of Medicinal Chemistry. 49:4455-4458
C-Jun NH2 terminal kinases (JNKs) are important cell signaling enzymes. JNK1 plays a central role in linking obesity and insulin resistance. JNK2 and JNK3 may be involved in inflammatory and neurological disorders, respectively. Small-molecule JNK in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc463ce3c72249463613b7043f83c6a3
https://doi.org/10.1021/jm060465l
https://doi.org/10.1021/jm060465l
Autor:
James M. Trevillyan, Elizabeth H. Fry, Eric F. Johnson, Chaohong Sun, Hing L. Sham, Charles W. Hutchins, Thomas H. Lubben, Bruce G. Szczepankiewicz, Edward T. Olejniczak, Michael A. Stashko, Cele Abad-Zapatero, Michael D. Serby, Rebecca J. Gum, Hongyu Zhao, Kristi Haskins, Zhili Xin, Bo Liu, Sarah A Dorwin, Jill E. Clampit, Nelson Lissa T, Gang Liu, Mei Liu, Christi Kosogof, Cristina M. Rondinone, Sanyi Wang, Deanna L. Haasch
Publikováno v:
Journal of Medicinal Chemistry. 49:3563-3580
The c-Jun N-terminal kinases (JNK-1, -2, and -3) are members of the mitogen activated protein (MAP) kinase family of enzymes. They are activated in response to certain cytokines, as well as by cellular stresses including chemotoxins, peroxides, and i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a5bb3bc96de29a87b4ec28bbfc5f96f
https://doi.org/10.1021/jm060199b
https://doi.org/10.1021/jm060199b
Autor:
Leigh Frost, Cristina M. Rondinone, Deanna L. Haasch, Cathleen E Berg, Terry Pederson, Paul E. Kroeger, Jill E. Clampit
Publikováno v:
Biochemical and Biophysical Research Communications. 343:361-368
Activation of PKCtheta is associated with lipid-induced insulin resistance and PKCtheta knockout mice are protected from the lipid-induced defects. However, the exact mechanism by which PKCtheta contributes to insulin resistance is not known. To inve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cf5736199c06b8b295db4bada8f70a5
https://doi.org/10.1016/j.bbrc.2006.02.177
https://doi.org/10.1016/j.bbrc.2006.02.177
Autor:
Gang Liu, Zhili Xin, James M. Trevillyan, Elizabeth H. Fry, Deanna L. Haasch, Rebecca J. Gum, Cele Abad-Zapatero, Jill E. Clampit, Sanyi Wang, Mei Liu, Hing L. Sham
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:2590-2594
A novel class of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as c-Jun-N-terminal kinase (JNK) inhibitors is described. These compounds were synthesized via the condensation of 2-nitrobenzaldehydes and hydroxypyrazoles. The structure–activit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb7aa9b2a85c03096204cc36631f7f17
https://doi.org/10.1016/j.bmcl.2006.02.046
https://doi.org/10.1016/j.bmcl.2006.02.046